Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature)

Abstract

The article contains the analysis of medical and biological publications from the global   database created by the National Centre for Biology Information (NCBI), an intramural   biotechnological division of the US National Library of Medicine. The authors have analyzed   publications of the recent ten years. Major results of study of erythropoietins and their   recombinant analogues have been generalized and systematized. There has been revealed the   significant potential of the preparations of this group to be studied and used. Major advantages   and drawbacks of erythropoietins and their recombinant analogues have been described. It has   been pointed out that a great variety of erythropoietins and darbepoetins speaks to the fact that   there is lack of “universe” erythropoietin meeting all the requirements. Genetically modified   erythropoietin having both – pharmacokinetics convenient for clinical application and all   properties of the natural analogue – is considered to be the most successful darbepoetin. This   property has been resulted from the fact that comparing to standard erythropoietin darbepoetin   has bigger molecular weight due to introduction of 2 complementary sites of glycosylation. This,   in turn, results in the increase of half-life period and, consequently, decreases application   frequency of the preparation that makes it more convenient to use comparing to erythropoietin.   Application of erythropoietin and its derivatives in stroke therapy in experimental animal models   undoubtedly has positive impact on the reduction of the infarction size and dynamics of recovery   of neurological status. Results of the analysis demonstrate that the studied preparations are more   effective in the early period following stroke than being applied in the later hours. However, there   has been revealed some insufficient knowledge in treatment of brain ischemic lesions and   ischemic heart disease.